Results 11 to 20 of about 1,449,700 (357)

Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity

mAbs, 2023
Clinical studies have shown that combination therapy of antibodies targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death-1 (PD-1) significantly improves clinical benefit over PD-1 antibody alone. However, broad application of this
X. Pang, Zhao-liang Huang, T. Zhong, Peng Zhang, Z. Wang, Michelle Xia, Baiyong Li   +6 more
semanticscholar   +1 more source

Bispecific antibody shuttles targeting CD98hc mediate efficient and long-lived brain delivery of IgGs

bioRxiv, 2023
The inability of antibodies and other biologics to penetrate the blood-brain barrier (BBB) is a key limitation to their use in diagnostic, imaging, and therapeutic applications.
Ghasidit Pornnoppadol, Layne G. Bond, Michael J. Lucas, J. Zupancic, Yun-Huai Kuo, Boya Zhang, C. Greineder, Peter M. Tessier   +7 more
semanticscholar   +1 more source

A Novel Anti-B7-H3 × Anti-CD3 Bispecific Antibody with Potent Antitumor Activity

Life, 2022
B7-H3 plays an important role in tumor apoptosis, proliferation, adhesion, angiogenesis, invasion, migration, and evasion of immune surveillance. It is overexpressed in various human solid tumor tissues.
Yan Feng, Kun Xie, Yanxin Yin, Bingyu Li, Chenyu Pi, Xiaoqing Xu, Tao Huang, Jingming Zhang, Bo Wang, Hua Gu, Jianmin Fang   +10 more
doaj   +1 more source

Anti‐PD‐1/Her2 Bispecific Antibody IBI315 Enhances the Treatment Effect of Her2‐Positive Gastric Cancer through Gasdermin B‐Cleavage Induced Pyroptosis

Advancement of science, 2023
The majority of patients with human epidermal growth factor receptor 2 (Her2)‐positive gastric cancer develop refractory to Her2‐targeted therapy, where upregulation of immune checkpoints plays an essential role.
Wu Lin, Yingzi Zhang, Yan Yang, Ben Lin, Mengjia Zhu, Jinling Xu, Yiran Chen, Weiwei Wu, Bingliang Chen, Xiangliu Chen, Jin Liu, Haohao Wang, F. Teng, Xiongfei Yu, Haiyong Wang, Jun Lu, Quan Zhou, L. Teng   +17 more
semanticscholar   +1 more source

Production of native bispecific antibodies in rabbits. [PDF]

PLoS ONE, 2010
BACKGROUND: A natural bispecific antibody, which can be produced by exchanging Fab arms of two IgG4 molecules, was first described in allergic patients receiving therapeutic injections with two distinct allergens.
Wei Wang, Ruihuan Xu, Jinming Li
doaj   +1 more source

Toxicity Profile of Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapies in Multiple Myeloma: Pathogenesis, Prevention and Management

Current Oncology, 2023
Multiple myeloma is the second-most common hematologic malignancy in adults worldwide. Despite ongoing advancement in therapeutic modalities, it remains an incurable disease with a 5-year survival rate of approximately 50%.
Mariam Markouli, F. Ullah, Serhan Unlu, Najiullah Omar, N. Lopetegui-Lia, Marissa R. Duco, F. Anwer, S. Raza, D. Dima   +8 more
semanticscholar   +1 more source

Bispecific antibodies and their applications [PDF]

Journal of Hematology & Oncology, 2015
Bispecific antibodies (BsAbs) recognize two different epitopes. This dual specificity opens up a wide range of applications, including redirecting T cells to tumor cells, blocking two different signaling pathways simultaneously, dual targeting of different disease mediators, and delivering payloads to targeted sites.
Mingju Hao, Zujian Wang, Gaowei Fan, Jinming Li   +3 more
openaire   +3 more sources

Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy

Frontiers in Immunology, 2023
The PD-1/PD-L1 signaling pathway plays a crucial role in cancer immune evasion, and the use of anti-PD-1/PD-L1 antibodies represents a significant milestone in cancer immunotherapy.
Tianye Li, Xinrun Wang, Mengke Niu, Mingli Wang, Jianwei Zhou, Kongming Wu, Ming Yi   +6 more
semanticscholar   +1 more source

Brain pharmacokinetics of mono- and bispecific amyloid-β antibodies in wild-type and Alzheimer’s disease mice measured by high cut-off microdialysis

Fluids and Barriers of the CNS, 2022
Background Treatment with amyloid-β (Aβ) targeting antibodies is a promising approach to remove Aβ brain pathology in Alzheimer's disease (AD) and possibly even slow down or stop progression of the disease.
Ulrika Julku, Mengfei Xiong, Elin Wik, Sahar Roshanbin, Dag Sehlin, Stina Syvänen   +5 more
doaj   +1 more source

Development of brain-penetrable antibody radioligands for in vivo PET imaging of amyloid-β and tau

Frontiers in Nuclear Medicine, 2023
IntroductionAlzheimer's disease (AD) is characterized by the misfolding and aggregation of two major proteins: amyloid-beta (Aβ) and tau. Antibody-based PET radioligands are desirable due to their high specificity and affinity; however, antibody uptake ...
Vinay Banka, Andrew Kelleher, Dag Sehlin, Greta Hultqvist, Einar M. Sigurdsson, Einar M. Sigurdsson, Stina Syvänen, Yu-Shin Ding   +7 more
doaj   +1 more source